Emcure Pharmaceuticals Board Meeting on Aug 6 to Approve Q1 FY27 Results

Emcure Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the first quarter of the fiscal year 2027, both on a standalone and consolidated basis. The company has also confirmed that the trading window for designated persons and their relatives, which closed on July 1, 2026, will remain shut until 48 hours after the declaration of these financial results, specifically until August 8, 2026, in compliance with insider trading regulations.